Anuj Singhal1, Darshan Bhakuni2, Vishal Marwaha3, Vivek Hande4, Garvit Bagga5. 1. Rheumatologist, INHS Asvini , Colaba, Mumbai, Maharashtra, India . 2. Consultant Rheumatologist, UB Area , Bareilley, Uttar Pradesh, India . 3. Rheumatologist, Command Hospital , Alipore, Kolkata, West Bengal, India . 4. Head, Department of Medicine, INHS Asvini , Colaba, Mumbai, Maharashtra, India . 5. Resident, Department of Medicine, INHS Asvini , Colaba, Mumbai, Maharashtra, India .
Abstract
INTRODUCTION: Ankylosing Spondylitis (AS) with non-steroidal anti-inflammatory drug (NSAID) therapeutic failure is treated with biologics. AIM: To compare the clinical outcomes of different biologics for Asian Indian patients with AS who have NSAID therapeutic failure. MATERIALS AND METHODS: Thirty-five AS patients with NSAID failure were administered Etanercept (n=15) (50mg SQ, weekly) or Infliximab (n=20) (5mg/kg IV every 2(nd) month) based on patient convenience or physician discretion as per 2015 ACR/SAA/SPARTAN recommendations. Baseline demographic details, time to diagnosis, disease duration, presence of low backache, early morning stiffness, peripheral joint and extraarticular involvement, ESR, CRP values and HLA-B27 score were obtained. Baseline values of scores of BASMI-3 and MASES were calculated. To monitor the disease activity, BASDAI and ASDAS-ESR scores were recorded at baseline, and after 6 months and 12 months of therapy initiation. STATISTICAL ANALYSIS: Comparison of means: independent samples t-test; comparison of parameters over time: repeated measures ANOVA. RESULTS: Both groups were comparable in all parameters at therapy initiation except in the baseline BASMI-3 score which was significantly higher in patients who received Etanercept. Over 12 months of treatment, the reduction in disease activity, as evidenced by reduction in the mean BASDAI and ASDAS-ESR scores was statistically significant for all patients when considered together, as well as when Etanercept and Infliximab were considered separately (p<0.0001 in all cases). However, there was no statistically significant difference in the magnitude of reduction in the mean BASDAI and ASDAS-ESR scores between patients who received Etanercept and those who received infliximab (p=0.696 and 0.618 respectively). CONCLUSION: Etanercept and Infliximab offer statistically similar reduction in disease severity in Asian Indian AS patients with NSAID failure. Further studies with larger sample size are warranted.
INTRODUCTION:Ankylosing Spondylitis (AS) with non-steroidal anti-inflammatory drug (NSAID) therapeutic failure is treated with biologics. AIM: To compare the clinical outcomes of different biologics for Asian Indian patients with AS who have NSAID therapeutic failure. MATERIALS AND METHODS: Thirty-five AS patients with NSAID failure were administered Etanercept (n=15) (50mg SQ, weekly) or Infliximab (n=20) (5mg/kg IV every 2(nd) month) based on patient convenience or physician discretion as per 2015 ACR/SAA/SPARTAN recommendations. Baseline demographic details, time to diagnosis, disease duration, presence of low backache, early morning stiffness, peripheral joint and extraarticular involvement, ESR, CRP values and HLA-B27 score were obtained. Baseline values of scores of BASMI-3 and MASES were calculated. To monitor the disease activity, BASDAI and ASDAS-ESR scores were recorded at baseline, and after 6 months and 12 months of therapy initiation. STATISTICAL ANALYSIS: Comparison of means: independent samples t-test; comparison of parameters over time: repeated measures ANOVA. RESULTS: Both groups were comparable in all parameters at therapy initiation except in the baseline BASMI-3 score which was significantly higher in patients who received Etanercept. Over 12 months of treatment, the reduction in disease activity, as evidenced by reduction in the mean BASDAI and ASDAS-ESR scores was statistically significant for all patients when considered together, as well as when Etanercept and Infliximab were considered separately (p<0.0001 in all cases). However, there was no statistically significant difference in the magnitude of reduction in the mean BASDAI and ASDAS-ESR scores between patients who received Etanercept and those who received infliximab (p=0.696 and 0.618 respectively). CONCLUSION: Etanercept and Infliximab offer statistically similar reduction in disease severity in Asian Indian AS patients with NSAID failure. Further studies with larger sample size are warranted.
Authors: Désirée van der Heijde; Alan Kivitz; Michael H Schiff; Joachim Sieper; Ben A C Dijkmans; Jürgen Braun; Maxime Dougados; John D Reveille; Robert L Wong; Hartmut Kupper; John C Davis Journal: Arthritis Rheum Date: 2006-07
Authors: J C Davis; D M van der Heijde; J Braun; M Dougados; J Cush; D Clegg; R D Inman; A Kivitz; L Zhou; A Solinger; W Tsuji Journal: Ann Rheum Dis Date: 2005-04-20 Impact factor: 19.103
Authors: Michael M Ward; Atul Deodhar; Elie A Akl; Andrew Lui; Joerg Ermann; Lianne S Gensler; Judith A Smith; David Borenstein; Jayme Hiratzka; Pamela F Weiss; Robert D Inman; Vikas Majithia; Nigil Haroon; Walter P Maksymowych; Janet Joyce; Bruce M Clark; Robert A Colbert; Mark P Figgie; David S Hallegua; Pamela E Prete; James T Rosenbaum; Judith A Stebulis; Filip van den Bosch; David T Y Yu; Amy S Miller; John D Reveille; Liron Caplan Journal: Arthritis Rheumatol Date: 2015-09-24 Impact factor: 10.995
Authors: M Rudwaleit; D van der Heijde; R Landewé; N Akkoc; J Brandt; C T Chou; M Dougados; F Huang; J Gu; Y Kirazli; F Van den Bosch; I Olivieri; E Roussou; S Scarpato; I J Sørensen; R Valle-Oñate; U Weber; J Wei; J Sieper Journal: Ann Rheum Dis Date: 2010-11-24 Impact factor: 19.103
Authors: Désirée van der Heijde; Ben Dijkmans; Piet Geusens; Joachim Sieper; Kimberly DeWoody; Paul Williamson; Jürgen Braun Journal: Arthritis Rheum Date: 2005-02
Authors: Robert D Inman; John C Davis; Désirée van der Heijde; Laura Diekman; Joachim Sieper; Sung Il Kim; Michael Mack; John Han; Sudha Visvanathan; Zhenhua Xu; Benjamin Hsu; Anna Beutler; Jürgen Braun Journal: Arthritis Rheum Date: 2008-11
Authors: Nathan Vastesaeger; Désirée van der Heijde; Robert D Inman; Yanxin Wang; Atul Deodhar; Benjamin Hsu; Mahboob U Rahman; Ben Dijkmans; Piet Geusens; Bert Vander Cruyssen; Eduardo Collantes; Joachim Sieper; Jürgen Braun Journal: Ann Rheum Dis Date: 2011-03-14 Impact factor: 19.103